Abstract
It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.
MeSH terms
-
Abortion, Therapeutic
-
Adult
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Autopsy
-
Cardiotoxicity
-
Female
-
Fetal Heart / drug effects
-
Fetal Heart / pathology
-
Heart Block / congenital*
-
Heart Block / diagnosis
-
Heart Block / drug therapy
-
Heart Block / immunology
-
Heart Block / pathology
-
Heart Diseases / chemically induced
-
Heart Diseases / pathology
-
Humans
-
Hydroxychloroquine / adverse effects
-
Hydroxychloroquine / therapeutic use*
-
Lupus Erythematosus, Systemic / diagnosis
-
Lupus Erythematosus, Systemic / drug therapy*
-
Lupus Erythematosus, Systemic / immunology
-
Pregnancy
-
Risk Factors
-
Treatment Outcome
Substances
-
Antirheumatic Agents
-
Hydroxychloroquine